Sun
Pharmaceutical Industries Limited is a Indian pharmaceutical company
headquartered in Mumbai with global operations (Indian multinational).
Sun
manufactures and markets pharmaceutical formulations and active pharmaceutical
ingredients (APIs)
The
company offers formulations in various therapeutic areas, such as Cardiology, Psychiatry, Neurology, Gastroenterology and Diabetes. It also
provides APIs.
Sun
Pharmaceuticals was established by Mr. Dilip Shanghvi in 1983 in Vapi with five
products to treat psychiatric disorders. Cardiology products were introduced in 1987
followed by Gastroenterology products in
1989.
Over
the years, Sun has acquired multiple pharmaceutical companies, mostly in stress
and successfully turned them around.
Sun
Pharma has been under pressure for the past two quarters due to one-time
charges due to merging Ranbaxy to itself along with compliance issues (USFDA)
at its manufacturing unit (Halol) and the erstwhile Ranbaxy manufacturing units.
However, the guidance for lower one-time expenses related to Ranbaxy merger indicates
that the worst is probably over.
The con-call
post the announcement of the Q2 indicated that Sun has already site transferred
Gleevec from Halol to another US FDA approved plant and Ranbaxy merger synergy
will be achieved ahead of schedule. Sun
has already sold a division of Ranbaxy (Solus and Solus Care) to Stride
Arcolabs for Rs 165 Crore to consolidate the CNS division.
Earlier
in September, Sun Pharma had announced plans to sell a manufacturing facility
in Ireland (previously owned by Ranbaxy) as part of its consolidation process post
the Ranbaxy merger
Post
Ranbaxy, Sun through one of its subsidies has agreed to acquire US-based
InSite Vision Inc. in a deal worth $48 million (about Rs.300 crore),
benefits of which should start coming in the future quarters. If media reports are to be believed, Sun is
in advanced talks to buy a portion of Swiss drug maker Novartis' portfolio of
old branded products in Japan in a deal estimated at $300 million (about Rs
2,000 crore). Japan is the world’s
second biggest market (by value) for pharmaceuticals. The deal if consummated should open up a new
market for Sun.
Sun
Pharma also expects to get the phase 3 trial data for its novel molecule -
MK3222, which was in licensed from Merck and is likely to be filed in CY 2017
Finally
Sun is trading at Rs 742/- which is a 38% discount from the high of Rs 1200.7
it achieved a few month back. Although
Sun Pharma is not a cheap stock by any means with a forward PE of 36.2, but I
think there is a lot of value in the stock as the earnings improve as the
Ranbaxy merger slowly achieves synergy and the new acquisitions starts brining
in more cash.
Sun's
low-cost advantage, strong brand recognition, and proven capability in
manufacturing complex products and turning around companies (Ranbaxy should be
turned around pretty soon) supports sustainable long-term profitability.
As the
news flow right now is negative for the company (USFDA warning to Halol plant),
the price of the stock is down and as the saying goes either you get good news
or good price.
I
would be buying into the stock in every dips with a holding horizon of 3 years
and my conviction is high that Sun will shine in the Indian Stock markets again
pretty soon. As the saying goes “make
hay when sun shines” I hope to make hay as the Sun starts shining again but
till then I will accumulate Sun Pharmaceuticals.
Disclaimer: This is my current opinion. I have a very small holding in Sun Pharma
right now which I plan to increase. I
might change my opinion at any time, buy more or sell what I have or short sell. Please consult your advisor before acting on
my opinion.
4 comments:
I would like to make some hay as well
Thanks
Thanks dada! I was looking to hear on the Sun and it's here.
Hope you found it useful
lots of hay
Post a Comment